Research ArticleArticle
Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials
Maarten Boers, Daniel Aletaha, Christopher M. Mela, Daniel G. Baker and Josef S. Smolen
The Journal of Rheumatology April 2016, jrheum.150932; DOI: https://doi.org/10.3899/jrheum.150932
Maarten Boers
From the Department of Epidemiology and Biostatistics, and Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, the Netherlands; Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria; Roche Products Ltd., Welwyn Garden City, UK; Janssen Research and Development, Spring House, Pennsylvania, USA. M. Boers, MD, PhD, MSc, Professor of Clinical Epidemiology, Department of Epidemiology and Biostatistics, VU University Medical Center; D. Aletaha, MD, MSc, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna; C.M. Mela, PhD, MSc, BSc, Clinical Development Scientist, Roche Products Ltd.; D.G. Baker, MD, Vice President Immunology, Janssen Research and Development; J.S. Smolen, MD, Professor of Medicine, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna. Address correspondence to Dr. M. Boers, Professor of Clinical Epidemiology, Department of Epidemiology and Biostatistics, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: eb@vumc.nl. Accepted for publication February 19, 2016.
Daniel Aletaha
From the Department of Epidemiology and Biostatistics, and Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, the Netherlands; Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria; Roche Products Ltd., Welwyn Garden City, UK; Janssen Research and Development, Spring House, Pennsylvania, USA. M. Boers, MD, PhD, MSc, Professor of Clinical Epidemiology, Department of Epidemiology and Biostatistics, VU University Medical Center; D. Aletaha, MD, MSc, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna; C.M. Mela, PhD, MSc, BSc, Clinical Development Scientist, Roche Products Ltd.; D.G. Baker, MD, Vice President Immunology, Janssen Research and Development; J.S. Smolen, MD, Professor of Medicine, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna. Address correspondence to Dr. M. Boers, Professor of Clinical Epidemiology, Department of Epidemiology and Biostatistics, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: eb@vumc.nl. Accepted for publication February 19, 2016.
Christopher M. Mela
From the Department of Epidemiology and Biostatistics, and Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, the Netherlands; Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria; Roche Products Ltd., Welwyn Garden City, UK; Janssen Research and Development, Spring House, Pennsylvania, USA. M. Boers, MD, PhD, MSc, Professor of Clinical Epidemiology, Department of Epidemiology and Biostatistics, VU University Medical Center; D. Aletaha, MD, MSc, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna; C.M. Mela, PhD, MSc, BSc, Clinical Development Scientist, Roche Products Ltd.; D.G. Baker, MD, Vice President Immunology, Janssen Research and Development; J.S. Smolen, MD, Professor of Medicine, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna. Address correspondence to Dr. M. Boers, Professor of Clinical Epidemiology, Department of Epidemiology and Biostatistics, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: eb@vumc.nl. Accepted for publication February 19, 2016.
Daniel G. Baker
From the Department of Epidemiology and Biostatistics, and Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, the Netherlands; Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria; Roche Products Ltd., Welwyn Garden City, UK; Janssen Research and Development, Spring House, Pennsylvania, USA. M. Boers, MD, PhD, MSc, Professor of Clinical Epidemiology, Department of Epidemiology and Biostatistics, VU University Medical Center; D. Aletaha, MD, MSc, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna; C.M. Mela, PhD, MSc, BSc, Clinical Development Scientist, Roche Products Ltd.; D.G. Baker, MD, Vice President Immunology, Janssen Research and Development; J.S. Smolen, MD, Professor of Medicine, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna. Address correspondence to Dr. M. Boers, Professor of Clinical Epidemiology, Department of Epidemiology and Biostatistics, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: eb@vumc.nl. Accepted for publication February 19, 2016.
Josef S. Smolen
From the Department of Epidemiology and Biostatistics, and Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, the Netherlands; Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria; Roche Products Ltd., Welwyn Garden City, UK; Janssen Research and Development, Spring House, Pennsylvania, USA. M. Boers, MD, PhD, MSc, Professor of Clinical Epidemiology, Department of Epidemiology and Biostatistics, VU University Medical Center; D. Aletaha, MD, MSc, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna; C.M. Mela, PhD, MSc, BSc, Clinical Development Scientist, Roche Products Ltd.; D.G. Baker, MD, Vice President Immunology, Janssen Research and Development; J.S. Smolen, MD, Professor of Medicine, Division of Rheumatology, Department of Medicine 3, Medical University of Vienna. Address correspondence to Dr. M. Boers, Professor of Clinical Epidemiology, Department of Epidemiology and Biostatistics, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail: eb@vumc.nl. Accepted for publication February 19, 2016.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials
Maarten Boers, Daniel Aletaha, Christopher M. Mela, Daniel G. Baker, Josef S. Smolen
The Journal of Rheumatology Apr 2016, jrheum.150932; DOI: 10.3899/jrheum.150932